Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals

Yahoo Finance • 5 days ago

3 Biotech Stocks With Upside Of Up To 80%

Tech heavy indices have taken a hit as investors question huge AI spending, which leaves many traders searching for growth stories that are tied less to data centers and more to hard science. That is where high risk, high potential biotech... Full story

Yahoo Finance • 12 days ago

Arrowhead Pharmaceuticals And 2 Biotech Stocks To Own

Biotech stocks live and die on access to capital, so the Federal Reserve's signal that interest rates may pause for now gives this high risk corner of the market some breathing room. Cheaper money can make it easier to fund drug pipelines... Full story

Yahoo Finance • 27 days ago

3 Biotech Stocks To Watch In October 2026

Rising U.S. interest rate expectations, highlighted by the St. Louis Fed hinting at possible hikes over the next 6 to 9 months, keep pressure on expensive, story driven assets. That focus on higher borrowing costs puts a premium on medical... Full story

Yahoo Finance • 27 days ago

Catalyst watch: Big bank earnings, CPI, and the Paris Auto Show

[Finance background] honglouwawa Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Read more about the events that may impact stock prices next week. MONDAY - OCTOBER 12 *... Full story

Yahoo Finance • 2 months ago

Goldman rebalances its long duration stock basket

[Interest rate percentage sign symbol finance investment graph chart] alexsl The Goldman Sachs equity team has rebalanced its Long Duration Basket amid rising interest rates. Equities usually struggle to digest sharp increases in interes... Full story

Yahoo Finance • 2 months ago

Notable healthcare headlines for the week: UnitedHealth, Amgen, and CooperCompanies in focus

Wall Street rallied on Friday after the latest consumer inflation report came in broadly in line with expectations, helping ease concerns over price pressures and supporting a rebound across risk assets. On Friday, the Dow Jones Industria... Full story

Yahoo Finance • 2 months ago

Is Invesco S&P MidCap 400 Pure Growth ETF (RFG) a Strong ETF Right Now?

Making its debut on 03/01/2006, smart beta exchange traded fund Invesco S&P MidCap 400 Pure Growth ETF (RFG) provides investors broad exposure to the Style Box - Mid Cap Growth category of the market. What Are Smart Beta ETFs? Products t... Full story

Yahoo Finance • 2 months ago

Arrowhead Pharmaceuticals Director Sells 11,600 Shares for $1 Million

Michael S. Perry, a Director at Arrowhead Pharmaceuticals (NASDAQ:ARWR), sold 11,600 shares of common stock on Aug. 18, 2026, according to an SEC Form 4 filing. Transaction summary Metric Value Transaction value $1 million Shares sold 11... Full story

Yahoo Finance • 2 months ago

Arrowhead Pharmaceuticals Presents Phase 3 SHASTA-3 and SHASTA-4 Data Demonstrating Plozasiran Reduced Acute Pancreatitis Events in Patients with Severe Hypertriglyceridemia

- Plozasiran reduced triglycerides (TG) by 79% and 81% versus placebo in SHASTA-3 and SHASTA-4 across the broad sHTG population - - More than 90% of plozasiran-treated patients achieved triglycerides below thresholds for AP risk, 500 mg/d... Full story

Yahoo Finance • 2 months ago

Arrowhead Pharmaceuticals to Present New Clinical Data at the European Society of Cardiology Congress

- Detailed results from the Phase 3 SHASTA-3 and SHASTA-4 Studies of Plozasiran in Patients with Severe Hypertriglyceridemia will be presented as a HOT LINE Late-Breaking Science Session on August 30, 2026 - - Arrowhead will host a webcas... Full story

Yahoo Finance • 3 months ago

Arrowhead Pharmaceuticals Inc (ARWR) (Q3 2026) Earnings Call Highlights: Strong Phase III Data ...

This article first appeared on GuruFocus. Net Loss: $194.3 million, or a loss of $1.36 per share, for the fiscal 2026 third quarter ended June 30, 2026. Revenue: Approximately $75 million for the quarter, up from $28 million in the prior... Full story

Yahoo Finance • 3 months ago

The 'Best-Case Scenario' That Shot Arrowhead Stock Sky-High

Arrowhead Pharmaceuticals' triglycerides-buster hit the "best-case scenario" in two studies Wednesday, leading the stock to skyrocket. Continue Reading... Full story

Yahoo Finance • 3 months ago

Ionis drops as Arrowhead posts late-stage trial win for lipid-lowering drug

[Up Down Arrows. Green And Red Color] Arrowhead Pharmaceuticals (ARWR [https://seekingalpha.com/symbol/ARWR]) on Wednesday announced a late-stage trial win for its lipid-lowering agent plozasiran in patients with severe hypertriglyceridem... Full story

Yahoo Finance • 4 months ago

Can Biogen Convince Skeptics That Cutting a Rogue Protein Slows Alzheimer’s?

Biogen will present detailed Phase 2 study data for its experimental Alzheimer’s drug diranersen at a conference in London. Continue Reading... Full story

Yahoo Finance • 4 months ago

3 Under-the-Radar Biotech Takeover Targets for the Next Pharma Buying Spree

Quick Read Crinetics Pharmaceuticals leads as the cleanest buyout candidate at $3.79 billion; Cytokinetics' FDA-approved Myqorzo attracts Bristol Myers Squibb or Novartis but costs $10.86 billion. ARWR's ARO-INHBE nearly doubled tirzepati... Full story

Yahoo Finance • 6 months ago

Arrowhead (ARWR) Rated Buy on Metabolic Pipeline Potential

Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) ranks among the most profitable biotech stocks to buy now. Following comments on Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR)’s obesity and metabolic illness initiatives, TD Cowen reiterated its... Full story

Yahoo Finance • 6 months ago

Complement Inhibitors Market Outlook Remains Strong During the Forecast Period (2026–2036) with Increasing Adoption of C5 and C3 Targeted Drugs | DelveInsight

DelveInsight Business Research LLP The complement inhibitors market is projected to grow, driven by the rising prevalence of complement-mediated diseases, intensified R&D efforts, and biotechnological advancements enabling novel therapeut... Full story

Yahoo Finance • 7 months ago

Stocks Erase Early Gains as Crude Prices Jump on Iran Concerns

The S&P 500 Index ($SPX) (SPY) today is down -0.13%, the Dow Jones Industrial Average ($DOWI) (DIA) is down -0.13%, and the Nasdaq 100 Index ($IUXX) (QQQ) is up +0.02%.  June E-mini S&P futures (ESM26) are down -0.13%, and June E-mini Nasd... Full story

Yahoo Finance • 8 months ago

Arrowhead (ARWR) FQ1 2026 Revenue Hits $264M as REDEMPLO Approval Marks Commercial Shift

Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) is one of the best multibagger stocks to invest in according to billionaires. On February 5, Arrowhead Pharmaceuticals achieved a strategic turning point in FQ1 2026, transitioning into a commer... Full story

Yahoo Finance • 9 months ago

Arrowhead price target lowered to $78 from $81 at Morgan Stanley

Morgan Stanley lowered the firm’s price target on Arrowhead (ARWR) to $78 from $81 and keeps an Equal Weight rating on the shares. Broad pipeline execution continues with multiple readouts expected later this year, including key Phase 3 SH... Full story